Before you sell to, join or invest in PATH EX, Inc.
MentionFox check on PATH EX, Inc.: only 1 source on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/path-ex-inc-form-d-25000001
Check PATH EX, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about PATH EX, Inc.?
Based on the record MentionFox holds for this company. No flag is not a clearance.
PATH EX, Inc. filed a Form D with the Securities and Exchange Commission on 2025-05-09.
PATH EX, Inc. filed a Form D notice of an exempt securities offering with the SEC on May 9, 2025. The filing reports $8.21M sold. Its industry group is Biotechnology. It names Sindead Miller (Executive Officer, Director), Ehsan Jabbarzadeh (Director), Jeffrey Burbank (Director) (SEC Form D, May 9, 2025).
Is this your company?
Sell to companies like PATH EX, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-05-09 · the record
Pitching, partnering or investing alongside them? See who really runs and owns PATH EX, Inc.
Free to see. No signup.
More on the people and the money behind PATH EX, Inc., from the filings we hold.
Biotechnology raises by companies based in Texas, filed in May 2025, largest first.
Get an email when PATH EX, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when PATH EX, Inc. raises, hires or launches. No email unless you switch it on.
Watch PATH EX, Inc. →Get the full cited report on PATH EX, Inc.
What the filing shows about PATH EX, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on PATH EX, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives PATH EX, Inc.'s address as 2450 Holcombe Blvd., Ste J, Houston, TX 77021.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
PATH EX, Inc. is a registered filer with the SEC (CIK 1705898) and has filed since 2025-05-09. 1 filing is on record, the latest on 2025-05-09.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
PATH EX, Inc.'s Form D of 2025-05-09 names Sindead Miller, Ehsan Jabbarzadeh and Jeffrey Burbank as its officers, directors or promoters.
Its new offerings report $8.21M sold across 1 offering, as its own filings state.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Sindead Miller is named as Executive Officer and Director on the Form D that PATH EX, Inc. filed with the SEC on 9 May 2025, one of 3 people that filing names.
Ehsan Jabbarzadeh is named as Director on the Form D that PATH EX, Inc. filed with the SEC on 9 May 2025, one of 3 people that filing names.
Jeffrey Burbank is named as Director on the Form D that PATH EX, Inc. filed with the SEC on 9 May 2025, one of 3 people that filing names.
3 people named on the filing — 1 holding an executive role and 2 as directors only.
Named as of the 2025-05-09 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about PATH EX, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on PATH EX, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on PATH EX, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist PATH EX, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind PATH EX, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for PATH EX, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Houston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/path-ex-inc-form-d-25000001